Symposium Honors Chief Scientific Officer, Dr. Volker Sandig
BERLIN, Germany, September 30, 2022 / B3C newswire / -- The biotechnology firm ProBioGen held the symposium "A New Dawn in Biotechnology: Innovative Solutions for Tomorrow's Medicines" in Berlin today in honor of its Chief Scientific Officer Dr. Volker Sandig's 60th birthday.
A group of world renowned speakers focused on:
- Highly targeted protein therapies, by Dr. Hitto Kaufmann, Pieris Pharmaceuticals, Inc.
- How "patients-on-a-chip" could impact health care, by Prof. Dr. Uwe Marx, TissUse GmbH
- Failing and trying again in R&D, by Prof. Dr. Ralf Wagner, University of Regensburg
- Cell culture-based virus production, by Dr. Yvonne Genzel, Max Planck Institute for Dynamics of Complex Technical Systems, and
- ProBioGen's contributions to new cancer therapy, by Dr. Scott Chappel, NextPoint Therapeutics, Inc.
"Working with Volker Sandig has always been an extraordinary innovation experience for me," said Prof. Dr. Uwe Marx, one of the speakers and back in 1994 ProBioGen's founder, honorary professor of medical biotechnology at the Technische Universität Berlin, and Chief Scientific Officer at TissUse GmbH. "His scientific discoveries in cell and vector biotechnology, as well as in vaccine technology, have changed the way we develop active ingredients and vaccines. I am curious to see what he and his team invent and implement next."
Dr. Sandig has worked at ProBioGen for 22 years. In 2000, he started the company's cell development program. He co-invented many ProBioGen technologies, including AGE1® designer cell lines, GlymaxX® and DirectedLuck®.
In 2019, he received the European Society for Animal Cell Technology Innovation Award. Currently, he is working on modernizing the manufacture of viral vectors and establishing new platforms for ribonucleic acid delivery.
"Volker Sandig for years is the scientific face of ProBioGen which I proudly can say also on behalf of Dr. Wafik Bardissi, Chairman and CEO of our mother company Minapharm Pharmaceuticals. Volker's reputation in the scientific world is recognized by hundreds of clients and impacted millions of patients," said ProBioGen Chief Executive Officer Dr. Lutz Hilbrich. "We're on the cusp of a new dawn in biotechnology. ProBioGen's team is fully prepared to embrace new technologies to help our clients develop better medicines. Ultimately, this will help more people live healthier, longer lives."
For high resolution please click the image.
ProBioGen is a Berlin-based biotech company, so-called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally. It specializes in developing and manufacturing biopharmaceutical active ingredients and vaccines, applying proprietary technologies to improve product quality and features. It started in 1994 as a spin-off of Charité, widely recognized as the best hospital in Germany. Twenty-eight years later, nearly 300 employees work at ProBioGen's three locations in Berlin. Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.
For more information about ProBioGen, follow us on LinkedIn.
Keywords: Humans; Congresses as Topic; Delivery of Health Care; Manufacturing and Industrial Facilities; Cell Culture Techniques; cell line development; Technology; Biotechnology; Berlin; Germany
Published by B3C newswire